Apollomics, Inc. Announces Initiation of SPARTA Phase 2 Clinical Trial for c-MET Inhibitor APL-101

On May 21, 2020 Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of oncology mono- and combination therapies, reported the initiation of the Phase 2 portion of the Phase 1/2 clinical trial for APL-101 based on completion of the Phase 1 and approval from the study’s safety review committee to advance the trial (Press release, Apollomics, MAY 21, 2020, View Source [SID1234558380]). APL-101 is a novel, orally administered, highly selective Type 1b class of c-MET inhibitor, an enzyme which has been shown to function abnormally in many malignant tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The APL-101 Phase 1/2 clinical trial is an international multicenter, open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of APL-101. The Phase 2 portion of the study, titled SPARTA, will evaluate activity in non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon 14 skipping, and across tumor types (pan-cancer) with MET amplification or fusions.

"Advancing APL-101 into our Phase 2 SPARTA trial is a major milestone for Apollomics as we strive to combat NSCLC MET exon 14 skipping and MET dysregulated tumors with precision," said Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer. "The incidence of MET dysregulations presents a critical need to identify patients who can benefit most from a targeted treatment, like APL-101, in order to optimize patient care. Over the past several years, we have established numerous partnerships with leading biopharma companies, and we continue to progress our robust research and development pipeline globally."

SPARTA will enroll patients into multiple cohorts. In NSCLC, the trial will evaluate both c-MET inhibitor naïve and experienced patients with mutations that lead to MET exon 14 skipping. Two cohorts will enroll patients with solid tumors with MET amplifications and fusions, including glioblastoma multiforme, the most aggressive form of brain cancer. The primary objective of SPARTA is to assess efficacy by overall response rate (ORR) and duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) or relevant evaluation criteria per tumor type. Secondary objectives include the incidence and severity of adverse events and additional efficacy measurements including time to progression, progression free survival, and overall survival.

"MET is dysregulated in several tumor types in addition to non-small cell lung cancer allowing for the possibility of broad applicability for a targeted treatment. Based on the tolerability data from the Phase 1 portion of SPARTA, and the emerging data observed in MET dysregulated NSCLC from a parallel ongoing Chinese Phase 1 trial, we are encouraged by the potential of APL-101. We look forward to further evaluation of APL-101 in the Phase 2 setting," added Mark Awad, M.D., Ph.D., SPARTA Principal Investigator, Assistant Professor of Medicine at Harvard Medical School and Clinical Director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute.

The Phase 1 portion of the study was completed in April 2020. In the study, APL-101 was generally safe and well-tolerated with no reported dose limiting toxicities, and the recommended Phase 2 dose was determined to be 200 mg twice daily (BID). Apollomics expects to present the results of the Phase 1 portion of the study at an upcoming medical meeting.

About c-MET Dysregulations

Dysregulation of the c-MET tyrosine kinase receptor is implicated in the development of tumor malignancy and can arise through several mechanisms, including gene fusion and amplification, overexpression of the receptor and/or its ligand hepatocyte growth factor (HGF), and the acquisition of activating mutations. One type of the activating mutations cause exon 14 to be skipped due to aberrant splicing of MET mRNA. MET exon 14 skipping occurs in approximately 3% of NSCLC and has been demonstrated to be an oncogenic driver, raising the possibility that tumors with these specific mutations will be largely sensitive to c-MET inhibitors.

About Non-Small Cell Lung Cancer (NSCLC)

Lung cancer is a disease in which malignant cancer cells form in the tissues of the lung. In 2017, there were an estimated 558,000 people living with lung and bronchus cancer in the United States, with new cases estimated to be over 228,000 in 2020. Lung cancer is also one of the more deadly cancers with a relative 5-year survival rate of around 20%. NSCLC is the most common type of lung cancer with about 80% to 85% of lung cancers falling into this category.

About APL-101

APL-101 is a novel small molecule kinase inhibitor that targets c-MET. It is a Type 1b class highly selective c-MET inhibitor. APL-101 has demonstrated strong tumor inhibitory effect in a variety of preclinical c-MET dysregulated human gastric, hepatic, pancreatic and lung cancer xenograft animal models and patient-derived xenograft models (PDX). In Phase 1 clinical trials, APL-101 (PLB1001) demonstrated a generally well-tolerated safety profile with preliminary evidence of clinical activity in NSCLC subjects harboring a mutation that leads to MET exon 14 skipping and in secondary glioblastoma multiforme (sGBM) patients harboring MET fusion and/or exon 14 skipping with evidence of brain penetration. In China, APL-101 is referred to as PLB1001 where it is being developed by Apollomics’ partner Beijing Pearl Biotechnology Co. Ltd. Details on the Phase 1/2 SPARTA clinical trial can be found on clinicaltrials.gov: NCT03175224. Apollomics is actively assessing the potential of investigating APL-101 in combination with novel therapies and in a variety of tumor types in addition to developing APL-101 as single-agent cancer therapy. APL-101 is currently under clinical investigation and not approved for any use anywhere in the world.

Wolters Kluwer Announces Publishing Collaboration with Leading Oncology Society

On May 21, 2020 Wolters Kluwer, Health, a leading global provider of information and point of care solutions for the healthcare industry, reported that it has entered into a multi-year agreement with the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), Inc. (ASCO) (Free ASCO Whitepaper), the world’s leading organization of its kind representing nearly 45,000 oncology professionals who care for people with cancer (Press release, Wolters Kluwer, MAY 21, 2020, View Source [SID1234558398]). Under this agreement, beginning in January 2021, Wolters Kluwer will publish ASCO (Free ASCO Whitepaper)’s portfolio of five medical specialty journals, including its flagship publication the Journal of Clinical Oncology (JCO), one of the most highly cited oncology journals in the world (Press release, Wolters Kluwer, MAY 21, 2020, View Source [SID1234558398]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wolters Kluwer will focus on expanding ASCO (Free ASCO Whitepaper)’s journal readership globally through access and distribution on the Ovid medical research platform, among other channels, as well as the potential to reach members and practitioners through new digital channels.

"This new collaboration with Wolters Kluwer represents an exciting opportunity for ASCO (Free ASCO Whitepaper)’s family of journals as we look to the future of publishing," said Clifford A. Hudis, MD, FACP, FASCO, Chief Executive Officer of ASCO (Free ASCO Whitepaper). "We are very pleased to now have Wolters Kluwer’s global position, expertise in medical specialty publishing, and digital solutions behind our journal portfolio. Ultimately, we believe this will help expand the reach of our content and help as many practitioners and cancer patients worldwide as possible."

"We are honored to be selected by the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) as their journal publisher to grow and expand the reach of this prestigious portfolio of oncology research and practice publications," said Greg Samios, President and CEO, Wolters Kluwer, Health Learning, Research & Practice. "As a leader in its field, ASCO (Free ASCO Whitepaper) is continually innovating to keep pace with both research and practice advancements. It is our privilege to partner with ASCO (Free ASCO Whitepaper)’s team to evolve and deliver new digital solutions that ensure practitioners have the latest evidence-based oncology research to improve patient care and outcomes."

ASCO’s journal publications include:

Journal of Clinical Oncology (JCO) – Publishes the field’s foremost peer-reviewed clinical cancer research and practice-changing clinical trials and is regarded as the authoritative resource on current information on the diagnosis and treatment of patients with cancer.
JCO Oncology Practice (JCO OP) – Provides content that keeps oncology practice current with changes and challenges inherent in providing quality oncology care, including research on oncology care delivery, practical clinical reviews, and select case reports.
JCO Clinical Cancer Informatics (JCO CCI) – Publishes a growing body of research in clinical care informatics methods and processes as applied to cancer-related data, information and images.
JCO Precision Oncology (JCO PO) – Publishes translational precision oncology research, reports, opinions and reviews that consider genomics and other biomarker-driven clinical care of patients with cancer.
JCO Global Oncology (JCO GO) – Publishes research that addresses the unique cancer diagnosis and care issues in settings around the world with constrained health care resources.
To learn more about the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), please visit their website, www.asco.org.

Read this story on our website.

ASCO is a registered trademark of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), Inc. Used with permission. ASCO (Free ASCO Whitepaper) is not a partner or affiliate of Wolters Kluwer and does not recommend or endorse any vendor, product, or service.

Incyte to Present at Upcoming Investor Conference

On May 21, 2020 Incyte (Nasdaq:INCY) reported that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference (held virtually) on Tuesday, June 9, 2020 at 8:00 a.m. ET (Press release, Incyte, MAY 21, 2020, View Source [SID1234558381]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

ADC Therapeutics Announces Loncastuximab Tesirine (Lonca) Clinical Data to be Presented at the Virtual 25th EHA Annual Congress

On May 21, 2020 ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, reported that interim clinical data on loncastuximab tesirine (Lonca, formerly ADCT-402) will be presented in an oral presentation and e-Poster at the virtual 25th Congress of the European Hematology Association (EHA) (Free EHA Whitepaper) (EHA25) (Press release, ADC Therapeutics, MAY 21, 2020, View Source [SID1234558399]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The oral presentation details are as follows:

Title: Initial Results of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Abstract: S233
Session: Aggressive lymphomas: Prospective studies
Presenter: Carmelo Carlo-Stella, MD, Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas University, Milan, Italy

The e-Poster details are as follows:

Title: Interim Results of a Phase 1/2 Study of Loncastuximab Tesirine (Lonca) Combined With Ibrutinib in Advanced Diffuse Large B-Cell Lymphoma (DLBCL) or Mantle Cell Lymphoma (MCL)
Abstract: EP1284
Session: 19. Aggressive Non-Hodgkin lymphoma – Clinical
Lead author: Julien Depaus, MD, Department of Hematology, CHU UCL Namur site Godinne, Yvoir, Belgium

The abstracts are available on the EHA (Free EHA Whitepaper) website at View Source Updated results that are not included in the abstracts will be presented. All oral presentations and e-Posters will be available for on-demand viewing to those registered for the meeting starting Friday, June 12, 2020, at 08:30 CEST / 2:30 a.m. EDT.

Day One Biopharmaceuticals shares plans to rapidly develop new cancer treatments for people of all ages and announces $60M Series A funding and lead clinical-stage program acquired through Takeda

On May 21, 2020 DAY ONE Biopharmaceuticals, LLC. Using new insights from the biology of pediatric cancer, Day One Biopharmaceuticals develops promising new oncology therapies that change outcomes for people of all ages (Press release, Day One, MAY 21, 2020, View Source [SID1234558435]). Today, Day One unveils its team, $60M Series A financing, and announces its first promising clinical-stage oncology treatment, which Day One acquired through Takeda Pharmaceutical Company Limited.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Advances in cancer research enable drug developers to identify children and adults who may benefit from the same medicine. Yet, children with cancer continue to be left behind. "In the US, children with cancer first gain access to cutting-edge investigational treatments an average of 6.5 years later than adults. This disparity in access occurs for multiple reasons, including the prioritization of adult cancers that can create larger markets; a development model that remains centered on adult conditions versus mechanism of action; and outdated assumptions around trial feasibility in pediatric oncology. As a result, only 10 new drugs for pediatric cancer have been FDA approved over the last 30 years," explained Dr. Samuel Blackman, co-founder, pediatric oncologist, and Chief Medical Officer of Day One. "Our goal is to dramatically change the pace of new cancer drug development for children by identifying and developing novel therapies based on pediatric cancer biology, and then following the biology to the benefit of all patients whether they are children or adults."

Enabled by advances in the understanding of the biology of childhood cancers, and informed by its network of leading pediatric oncologists, Day One is equipped to identify patients across the age spectrum who are likely to benefit from a new treatment based upon their tumor’s biology. In parallel, Day One leverages improvements in pediatric oncology clinical trial infrastructure and modern study designs to execute faster and more efficient clinical trials for children with cancer. "This confluence allows new targeted therapies to be developed for both childhood and adult cancers with equal speed and intensity. A small focused company, like Day One, can execute rapidly to deliver new treatments for people with cancer. I am delighted to back Day One on this mission, " Dr. Daniel Becker, Principal at Access Biotechnology.

Day One was incubated at Canaan through a focused effort to identify, acquire, and develop promising new treatments that could address childhood cancers. "Cancer impacts patients of all ages. New treatments should, too," noted Julie Grant, acting-CEO at Day One and General Partner at Canaan. "At Day One we ask – what is the fastest path to FDA approval and insurance coverage for this product? Treating patients whose tumors are most likely to respond to treatment, irrespective of age, as quickly as possible is a simple and often underutilized strategy. Our team is focused on development innovation and rapid execution, in addition to being at the forefront of cancer biology."

To execute on its strategy, Day One recruited a deeply experienced and creative team of drug developers to urgently pursue innovative clinical trials for children and adults with cancer. Details about Day One’s team can be found here. Day One’s extended community of supporters also includes leading physician-scientists and clinical investigators who help inform Day One’s translational and clinical plans, and members of the patient/parent advocacy community who ensure patient-centricity and a focus on the greatest unmet needs. "It is clear that Day One was purpose-built to serve the mission of accelerating pediatric oncology drug development," notes Dr. Daphne Haas-Kogan, Chair of the Department of Radiation Oncology at the Dana-Farber Cancer Institute, who treats both children and adults with cancer. "The depth and experience of their team, their deep commitment to the needs of these patients and their families, and their willingness to include families, investigators, and regulators from the start are unparalleled."

Day One also announced today that it acquired Takeda’s rights to develop and commercialize DAY101 (formerly TAK-580) worldwide, including certain rights previously licensed by Takeda from Sunesis Pharmaceuticals. In parallel, Day One re-negotiated with Sunesis the terms of the licensing agreement acquired from Takeda. Takeda retains license to develop and commercialize DAY101 in certain rare disease indications.

"With its strong expertise in pediatric oncology, Day One is the ideal partner to continue advancing DAY101, which may one day provide a new treatment option for children with relapsed gliomas," said Chris Arendt, PhD, Head of Takeda’s Oncology Therapeutic Area Unit.

DAY101 is a potent selective oral, once-a-week, small molecule type II inhibitor of RAF, an oncogenic driver in a range of cancers including pediatric glioma and adult solid tumors. Over 250 patients have received DAY101 in clinical trials thus far. DAY101 demonstrated early clinical activity across adult and pediatric populations with specific genetic alterations in the RAS/MAP kinase pathway. Details of the clinical safety and efficacy data will be announced in 2020 and 2021.

Tumors harboring genetic alterations, such as BRAF wildtype fusions, BRAF mutations, and other alterations in the MAPK pathway could be addressed by DAY101. Many of these populations cannot be adequately treated with incumbent BRAF or MEK inhibitors. Michael Gladstone, Principal at Atlas Venture, said "Targeted oncology therapies in the RAS/MAP kinase pathway can deliver tremendous benefit to patients young and old. Our priority is developing DAY101 as both a monotherapy and in combination with complementary therapies to treat a range of aggressive cancers that are not served by existing drugs." Canaan, Access Biotechnology, and Atlas Venture jointly funded the $60M series A round to develop DAY101 and to expand the pipeline through additional partnerships.

An investigator sponsored trial of DAY101 to treat children with relapsed pediatric glioma is ongoing through the Pacific Pediatric Neuro-Oncology Consortium. The preclinical work establishing the potential of DAY101 in pediatric glioma was performed by grants from a range of philanthropic organizations including the PLGA Fund at PBTF, the Team Jack Foundation, Team Nathan and Takeda.